Inotek Pharmaceuticals Corp. RCKT 深 滬
交易中 07-18 11:51:54 美东时间
3.26
-0.080
-2.40%
華盛通- 最 高3.33
- 今 開3.33
- 成交量 132.74万股
- 最 低 3.13
- 昨 收 3.34
- 總市值 3.52亿
- 52周最高 25.40
- 市盈率 靜 --
- 換手率 1.23%
- 52周最低 2.19
- 委 比 -5.52%
- 總股本 1.08亿
- 歷史最高 67.48
- 量 比 1.06
- 振 幅 5.99%
- 歷史最低 2.19
- 每 手 1
- 風險率 4.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Rocket Pharmaceuticals Receives FDA RMAT Designation
Rocket Pharmaceuticals ( ($RCKT) ) has provided an announcement. On July 17, 20...
07-17 20:15
ATTENTION NASDAQ: RCKT INVESTORS: Contact Berger Montague About a Rocket Pharmaceuticals Class Action Lawsuit
PHILADELPHIA, July 15, 2025 /PRNewswire/ -- Berger Montague PC, a nationally recognized securities litigation firm based in Philadelphia, announces it is investigating a newly filed securiti...
07-16 04:06
Rocket Pharma Receives FDA Clearance For IND Application For RP-A701, Aavrh.74-Based Gene Therapy Candidate For Treatment Of BAG3-Associated Dilated Cardiomyopathy
RP-A701 is a first-in-class gene therapy for the treatment of BAG3-associated dilated cardiomyopathyBAG3-associated dilated cardiomyopathy is a rare, inherited heart condition caused by mutations in the BAG3 gene,
06-30 19:10
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
UBS Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $5
UBS analyst Colin Bristow maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price target from $12 to $5.
06-17 21:36
美股大行评级 | 潜在涨幅417.8%！RBC Capital上调Perspective Therapeutics目标价至16美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1136940401951563776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• RBC Capital：维持Perspective Therapeutics(CATX)"跑赢大市"评级，目标价从15美元升至16美元</p> <p>• Canaccord Genuity：维持Taysha Gene Th
06-04 08:35
Canaccord Genuity Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $11
Canaccord Genuity analyst Whitney Ijem maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price target from $34 to $11.
06-03 19:36
Rocket Pharmaceuticals Analyst Ratings
Unity Software(U.US) reported fourth-quarter financial results after the market...
06-03 19:35
Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
05-31 20:04
美股大行评级 | 英伟达、赛富时、C3.ai、Veeva Systems等获多家机构上调目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1135136987677396993.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Cogent Biosciences(COGT)"超配"评级，目标价从21美元升至25美元</p> <p>• Chardan Capital：维持Taysha Gene Therapies(TSHA)"买入"
05-30 09:09
